rucaparib

August 31, 2020August 31, 2020

FDA Approves Blood Test That Can Identify Cancers Eligible for Targeted Therapies

News

The U.S. Food and Drug Administration (FDA) has approved FoundationOne Liquid CDx, a blood test that can be used to identify cancer patients who may benefit from certain targeted therapies, including ... Read more

October 24, 2018

Rubraca Shrank Tumors in Nearly Half of Advanced Prostate Cancer Patients with BRCA Mutations

News

Rubraca (rucaparib), Clovis Oncology‘s PARP inhibitor, shrank tumors in 44% of metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA mutations included in a Phase 2 clinical trial, the company announced. ... Read more

October 8, 2018October 10, 2018

Ovarian Cancer Treatment Named Breakthrough Therapy with Potential in Advanced Prostate Cancers

News

An approved therapy for advanced ovarian cancer — Rubraca (rucaparib) by Clovis Oncology — has been designated a breakthrough therapy by the U.S. Food and Drug Administration as a potential treatment for metastatic castration-resistant ... Read more

August 7, 2017

BMS and Clovis to Study Opdivo, Rubraca Combo Treatment in Prostate, Other Cancers

News

Bristol-Myers Squibb and Clovis Oncology will collaborate to assess the combination of Opdivo (nivolumab) and Rubraca (rucaparib) in Phase 2 and 3 clinical studies in patients with different cancer types, including ... Read more

February 7, 2017

Strata to Help Clovis Find Patients for Prostate Cancer Trials of Rucaparib

News

Strata Oncology will help Clovis Oncology accelerate patient enrollment in ongoing clinical trials assessing Clovis’ rucaparib as a treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA or ATM mutations. Strata is conducting ... Read more